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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.04.001Bendamustine is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL)
and B-cell non-Hodgkin lymphoma. There are scant reports on bendamustine-induced immune hemolytic
anemia occurring mainly in CLL patients. We report a case of immune hemolytic anemia that developed
after exposure to bendamustine in a 70-year-old female with CLL who was previously exposed to fludar-
abine. Previous exposure to fludarabine is a common finding in the majority of reported cases of benda-
mustine drug-induced immune hemolytic anemia (DIIHA), including our case. Bendamustine should be
suspected as the cause of any hemolytic anemia that develops while on this drug, especially in CLL
patients treated previously with fludarabine.
KEYWORDS: CLL; Bendamustine; Hemolytic anemiaCASE DESCRIPTION
he patient is a 70-year-old female diagnosed with
chronic lymphocytic leukemia (CLL) in 2005
(Rai stage I) and followed up conservatively
without treatment. In 2008, due to development of
constitutional symptoms related to her disease, she
received two cycles of ﬂudarabine and cyclophospha-
mide with satisfactory response. Five to six months
later, she developed direct antiglobulin test (DAT)-
negative hemolytic anemia that responded to a course
of steroids. In 2010, the patient developed marked
and symptomatic splenomegaly, and was started on
chemoimmunotherapy consisting of bendamustine
and rituximab. She tolerated the ﬁrst cycle fairly well.
However, due to infusion reaction during the second
cycle of rituximab, it was subsequently discontinued
and she remained on single agent bendamustine.
She received a total of four cycles of bendamustine,
with the last cycle in June 2010 resulting in afavorable response and a remarkable decrease in the
size of the spleen. Notably, following the third cycle
of bendamustine, she had mild hyperbilirubinemia
in the 2–2.5 mg/dL range, accompanied by decreased
haptoglobin at 24 mg/dL, and elevated absolute retic-
ulocyte count of 200,000/lL, albeit with stable hemo-
globin and LDH levels, and negative DAT. This
hemolytic process was felt to be related to the signif-
icant reduction of spleen size as a response to chemo-
therapy. Another possible explanation would be
immune hemolytic anemia related to bendamustine
that was inhibited by the recent exposure to ritux-
imab. Over the following six to eight months, the
bilirubin levels slowly trended down and stabilized
at around 1.4–1.5 mg/dL, and haptoglobin levels nor-
malized. The patient remained relatively asymptom-
atic from her disease and was managed by
observation at regular ofﬁce visits, CBC testing and
periodic abdominal ultrasound to re-assess liver and
spleen size. In January 2011, her white blood cellarter 2014
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(WBC) count rose gradually, reaching 185,000/lL in
August 2012. Meanwhile, she developed fatigue, body
aches, and left upper quadrant abdominal tenderness,
which were felt to be disease-related.
The patient restarted chemotherapy with single
agent bendamustine at a reduced dose of 70 mg/m2
with intent to reintroduce rituximab after her total
white count decreased and if the bendamustine
treatment was well tolerated. The patient responded
to treatment with a signiﬁcant decrease in her white
count. However, following her third cycle of benda-
mustine, a drop in her hemoglobin from 12.8 to
9.9 g/dL was noted. It was accompanied by a rise in
total bilirubin to 2.3 mg/dL. During that time, the
patient was complaining of fatigue and chills, and
had become slightly jaundiced. Further workup
revealed reticulocyte count of 3.6%, haptoglobin less
than 3 mg/dL, LDH 262 IU/L, and DAT associated
with RBC-bound IgG, and C3 with the antibody
identity showing autoantibody. An eluate from the
patient’s RBCs contained autoantibodies. Given the
association with bendamustine exposure, the absence
of recent use of potentially offending agents as well
as the concomitant disease response to treatment
manifested by reduced lymphocytosis and improve-
ment in her disease related symptoms, it was felt that
this autoimmune hemolytic anemia was related to
bendamustine use. Subsequently, bendamustine was
discontinued and the patient was started on predni-
sone 20 mg once daily and achieved a good response.
However, her hemoglobin dropped again when the
dose was tapered to 5 mg daily; this was increased
to 60 mg daily, which resulted in normalization of
her hemoglobin levels. After that, the dose was slowly
tapered down and was completely stopped after six
months. The patient’s hemoglobin remains stable.DISCUSSION
After the ﬁrst report of an immune mediated hemo-
lytic anemia secondary to a drug in 1953,1 the list
of drugs implicated in this phenomena continued to
expand, reaching 125 in 2007 in an update by
Garratty et al.2 Many of these reports were not sup-
ported by serologic evidence of immune mechanism
for the hemolytic process. Therefore, conﬁrmed
drug-induced immune hemolytic anemia (DIIHA) is
quite rare and its incidence is estimated to be one
per million of the population, which exceeds the inci-
dence of drug-induced immune thrombocytopenia or
neutropenia.3–6 There are two antibody types, and
therefore two primary mechanisms, by which a drug
can induce an immune hemolytic anemia. The ﬁrstHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014type is drug-dependent, reacting with RBCs in vitro
in the presence of a drug. Hemolysis will cease after
the drug is stopped. The second type of antibody is
drug-independent, which will react with RBCs
in vitro without the presence of a drug. Such antibod-
ies appear to be autoantibodies rather than antibodies
to the drug itself, producing a hematologic picture
identical to idiopathic warm autoimmune hemolytic
anemia (WAIHA). After removing the offending
drug, a hematological response will be noticed in
one to two weeks, but the DAT will remain positive
for several months.3,7 The prototype drug is methyl-
dopa, but today the most common drug to cause
WAIHA is ﬂudarabine. Proving that a certain drug
causes WAIHA in vitro is difﬁcult as in vitro testing
is of no value; the only clue is resolution of hemolysis
after the drug is stopped, but this can be confounded
by a concomitant use of steroids.
Bendamustine hydrochloride is an alkylating agent
ﬁrst designed in 1963 by Ozegowski and Krebs in
East Germany, and rediscovered in the 1990s. In
2008, it received FDA approval for ﬁrst line treatment
of patients with CLL as well as for patients with indo-
lent B-cell non-Hodgkin lymphoma (NHL) that pro-
gressed during or within six months of treatment with
rituximab or a rituximab-containing regimen. Chemi-
cally, bendamustine is composed of three structural
components: the mechlorethamine (nitrogen mus-
tard) group, which is structurally similar to cyclophos-
phamide and chlorambucil, and gives the drug its
alkylating properties; a benzimidazole ring, which is
similar in conﬁguration to some purine analogs such
as 2-chlorodeoxyadenosine, and represents a unique
facet of the molecule; and ﬁnally, a butyric acid side
chain. The purpose of adding this purine-like to the
nitrogen mustard was to include the antimetabolite
properties shown for benzimidazole, but no evidence
exists to conﬁrm antimetabolite functionality.8
There are ten reports of bendamustine-related
hemolytic anemia in the literature.9–12 Nine of these
cases occurred in CLL patients and one in a follicular
lymphoma (FL) patient. Only two cases took place in a
treatment naïve patient. Bendamustine dose ranged
between 70 and 100 mg/m2. DAT was negative in
three cases, not available in two, and positive in the
other ﬁve cases. Five patients were previously treated
with ﬂudarabine, and four of these had prior hemolytic
anemia related to ﬂudarabine. There are no reports of
bendamustine-induced hemolytic anemia in malignan-
cies other than CLL (except one case of FL as noted
above). This is in agreement with the known associa-
tion of CLL with autoimmune and drug-induced
hemolytic anemia (DIIHA), including two of the most163
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frequently used agents in this disease (chlorambucil
and ﬂudarabine). The exact mechanism leading to
the development of immune hemolysis in CLL is
unclear. Existing evidence suggests acquired T-cell
dysregulation mediating autoimmunity, and for CLL
cells producing inhibitory cytokines such as IL10
and IL6, which alter immunologic tolerance.13–15
In our case report, there are a number of ﬁndings
that support the diagnosis of bendamustine DIIHA.
First, the chronological association with exposure to
bendamustine. Second, the exclusion of other poten-
tial etiologies such as other drugs or viral infections.
Third, the concomitant response of CLL to treat-
ment, both clinical and hematological, which renders
the patient’s leukemia a less probable cause. Fourth,
a history of exposure to ﬂudarabine. As suggested
by other reports1 and from observations of previous
case reports where ﬁve out of ten cases were ﬂudara-
bine-exposed patients – including four who developed
ﬂudarabine-related hemolytic anemia – it seems that
prior exposure to and/or hemolytic anemia induced
by ﬂudarabine is emerging as a risk factor for hemo-
lytic anemia upon future administration of bendamus-
tine. The structural similarity between the two agents,
more speciﬁcally the purine ring, might serve as a sen-
sitizing factor leading to a more pronounced immuno-
logic reaction upon subsequent exposure to the other
drug. Fifth, a history of hemolytic episode in associa-
tion with previous bendamustine use. The possibility
of bendamustine-induced immune hemolytic anemia
during the above mentioned episode should still be
entertained despite a negative DAT which could have
been masked by the recent exposure to rituximab, a
phenomena that was previously described in theliterature.16 Notably, given that the eluate from the
patient’s RBC was positive for drug-independent
autoantibodies, the possibility of coinciding AIHA
secondary to CLL should also be considered in this
case. One can postulate that a leukemic clone emerged
after suppression of the other clones via effective
chemotherapy and triggered an autoimmune process
that resulted in hemolytic anemia. However, the
conversion of DAT from a negative to a positive after
bendamustine exposure is further support of the
involvement of bendamustine in the hemolytic event.
In the absence of a laboratory test or method that
can reliably distinguish drug-independent/drug-
mediated immune hemolytic anemia from AIHA
related to CLL, the diagnosis of bendamustine-induced
immune hemolytic anemia in this case remains equiv-
ocal, albeit very suspicious. A possible mechanism for
immune hemolysis related to bendamustine is
depletion of CD4 cells – in a similar fashion to the
lymphopenic effects of the other purine analogues –
which can lead to failure of control of autoreactive
T-cells.
This case adds to the accumulating data which
indicate that bendamustine administered to CLL
patients can potentially induce an autoimmune hemo-
lytic event, especially in those who previously received
and developed a hemolytic reaction to ﬂudarabine.
Therefore, should such an event occur while a patient
is on bendamustine, withholding the drug and avoid-
ing future exposure should be strongly considered.CONFLICT OF INTEREST
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